Geisinger CEO won’t lead Amazon-Berkshire-JPMorgan healthcare partnership

CNBC reported on May 7 that Geisinger Health System CEO David Feinberg, MD, was the top pick to lead the healthcare venture run by Amazon, Berkshire Hathaway and JPMorgan Chase. Within hours, Feinberg said he wouldn’t be leaving Geisinger but “appreciated being part of the conversation.”

The vaguely defined partnership has been hyped as a sign of impending Silicon Valley-esque disruption for healthcare, while others have seen little more than another group purchasing organization by large employers. The CNBC report indicated the companies are aiming for more based on what they asked CEO candidates, with the top ten choices tasked with writing a whitepaper on how they would fix the U.S. healthcare system.

That list of ten was then narrowed down to three. According to CNBC, JPMorgan CEO Jamie Dimon would interview those three choices, eliminating one and sending the two to Berkshire’s Warren Buffett. Then Buffet’s top choice would meet with Amazon CEO Jeff Bezos, who would have the power to veto the pick.

Buffett and Dimon had announced on the morning of May 7 that the final candidate had been selected and a public announcement would be coming in the next two weeks. After CNBC’s initial report, Feinberg said he’ll be staying at Geisinger, though CNBC stuck by its sources who said he was the top choice at one point.

“I personally remain 100 percent committed to Geisinger and remain excited about the work we are doing and the opportunities ahead as we continue to deliver exceptional care to our patients, our members and our communities,” Feinberg said in a statement.

CNBC had reported in March three other names were on the CEO shortlist: former acting administrator of CMS Andy Slavitt, former U.S. chief technology officer and Castlight Health co-founder Todd Park and Gary Loveman, a former senior executive at Aetna. Both Slavitt and Park quickly refuted those rumors, saying they didn’t want the job.

Read more at the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.